Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Humira Biosimilar Interchangeability: The Race Begins

Jul 30 2017

• By Derrick Gingery

Identical twins — Is pink interchangeable with yellow?

Related Content

Biosimilar Interchangeability May Be Losing Luster As Approval Goal

Sep 13 2016

Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Jul 22 2016

Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

Jul 15 2016

Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts

Apr 22 2017

Make Interchangeability Great Again: Biosimilar Switching Studies Need US Comparators

Jan 19 2017

Biosimilar Interchangeability: How To Design A Multiple-Switch Study

Jan 19 2017

Pending Biosimilars

Feb 13 2017

Humira's Inevitable Decline: What's Waiting In The Wings?

Mar 08 2017

Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting

Aug 05 2016

Related Companies

Boehringer Ingelheim GmbH

AbbVie Inc.

Novartis AG

Amgen, Inc.

Samsung Bioepis Co., Ltd.

Johnson & Johnson

Outlook Therapeutics, Inc.

Pfizer Inc.

Momenta Pharmaceuticals, Inc.

Coherus Oncology, Inc.

Additional Topics

United States Biosimilars Clinical Trials Regulation Inflammation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.